| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8707618 | Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology | 2018 | 20 Pages |
Abstract
Replacing ZA with denosumab is a risk factor for the development of ONJ. Both binding of bisphosphonate to bone and receptor activator of nuclear factor-κ B ligand inhibition could additively increase the risk of ONJ. We bring the replacement of ZA with denosumab to the attention of clinical oncologists.
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
Tomoko DDS, Yoshihiko DDS, PhD, Misato DDS, Makoto Ph, PhD, Yoshihisa Ph, PhD, Toshiaki Ph, PhD, Akira DDS, PhD,